Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IRE: Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer

NCT02343835 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.

NCT NCT02343835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02343835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IRE: Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
Lead sponsor
Fuda Cancer Hospital, Guangzhou
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2015
Completion date
May 1, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer